cyclosporine has been researched along with Adverse Drug Event in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.82) | 18.2507 |
| 2000's | 14 (31.82) | 29.6817 |
| 2010's | 19 (43.18) | 24.3611 |
| 2020's | 8 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Blake, K; Bonelli, M; Garcia Arieta, A; Gouveia, LF; Guerreiro, RB; Morais, JAG; Paixão, P; Silva, N | 1 |
| Viviano, KR | 1 |
| Deshpande, GA; Fukui, S; Kaname, S; Kishimoto, M; Komagata, Y; Ohyama, M | 1 |
| Dunn, CL; Dunn, CP; Petroni, DH | 1 |
| Bei, W; Feng, H; Kai, C; Liuqing, C; Qian, J; Ruili, J; Zilu, Q | 1 |
| Hawkshaw, NJ; Paus, R | 1 |
| Dash, S; Mishra, S; Sirka, CS; Viswan, P | 1 |
| Bacle, A; Chemouny, JM; Le Corre, P; Le Daré, B; Lhermitte, R; Mercerolle, M; Vigneau, C | 1 |
| Eder, IE; Guenther, J; Loeschenberger, B; Neuwirt, H; Niess, L; Puhr, M; Rudnicki, M; Schwelberger, H; Troppmair, J; Würzner, R | 1 |
| Christensen, B; Cohen, RD; Colman, RJ; Gibson, PR; Goeppinger, SR; Kassim, O; Micic, D; Rubin, DT; Weber, CR; Yarur, A | 1 |
| Hu, B; Kuang, F; Liu, D; Qing, S; Yang, Y; Yu, X | 1 |
| Bush, ED; Fabian, E; Herold, M; Kamp, HG; Krennrich, G; Looser, R; Mattes, WB; Mellert, W; Moeller, N; Nadanaciva, S; Naraoka, H; Omura, K; Piccoli, SP; Prokoudine, A; Ruiz-Noppinger, P; Schuppe-Koistinen, I; Strauss, V; van Ravenzwaay, B; Walk, T | 1 |
| Alberti, A; Brass, C; Buti, M; Calistru, P; Chuang, WL; Davis, GL; Flisiak, R; Goeser, T; Horban, A; Kao, JH; Mazzella, G; Orsenigo, R; Pol, S; Rasenack, J; Streinu-Cercel, A; Tabak, F | 1 |
| Gore, E; Groothuis, GM; Olinga, P; Pennings, JL; Vatakuti, S | 1 |
| Cooper, A; Harris, V; Jackson, C | 1 |
| Chang, HR; Cheng, CH; Chiang, CW; Chou, MC; Shu, KH | 1 |
| Nagami, GT; Paige, NM | 1 |
| Alves, OL; Brophy, GM; Bullock, MR; Gilman, CB; Hayes, RL; Mazzeo, AT; Povlishock, JT; Robles, JR | 1 |
| Ferkl, M; Vítko, S | 1 |
| Bobadilla, NA; Bonventre, JV; Collings, FB; Cordier, A; Dieterle, F; Gerhold, D; Goering, PL; Holder, DJ; Marrer, E; Maurer, G; Muniappa, N; Ozer, JS; Perentes, E; Ramirez, V; Sistare, FD; Thudium, D; Troth, S; Vaidya, VS; Vonderscher, J | 1 |
| Legendre, C; Pallet, N | 1 |
| Budde, K; Glander, P; Mashreghi, MF; Matz, M; Naik, M; Neumayer, HH | 1 |
| Bouwman, FG; Kleinjans, JC; Mariman, EC; Noben, JP; Renes, J; van Delft, JH; Van Summeren, A | 1 |
| Dewanji, A; Ghosh, P | 1 |
| Furuhashi, T; Kaneko, N; Morita, A; Saito, C; Shintani, Y | 1 |
| Andoh, TF; Bennett, WM; Burdmann, EA; Yu, L | 1 |
| Gore, ER; Herzyk, DJ | 1 |
| Baelde, HJ; Bruijn, JA; de Heer, E; Eikmans, M; Ijpelaar, DH | 1 |
| Ferguson, R; Knoflach, A; Kunzendorf, U; Mulgaonkar, S; Oppenheimer, F; Patel, Y; Russ, G; Tedesco, H; Walker, R | 1 |
| Deng, WF; Du, CF; Fu, SJ; Liu, XY; Wang, YB; Xu, J; Ye, GR; Yu, LX; Zhang, YX | 1 |
| Cordonnier, M | 1 |
| Bellisai, F; Galeazzi, M; Giannitti, C; Manganelli, S; Morozzi, G; Sebastiani, GD | 1 |
| Naldi, L | 1 |
| Andersen, WK; Feingold, DS | 1 |
| Handjiski, B; Maurer, M; Paus, R | 1 |
| Bernstein, RM | 1 |
| Anderson, NL; Steiner, S | 1 |
12 review(s) available for cyclosporine and Adverse Drug Event
| Article | Year |
|---|---|
Glucocorticoids, Cyclosporine, Azathioprine, Chlorambucil, and Mycophenolate in Dogs and Cats: Clinical Uses, Pharmacology, and Side Effects.
Topics: Animals; Azathioprine; Cat Diseases; Cats; Chlorambucil; Cyclosporine; Dog Diseases; Dogs; Drug-Related Side Effects and Adverse Reactions; Glucocorticoids; Immunosuppressive Agents | 2022 |
Comparing four immunosuppressive agents for chronic spontaneous urticaria-A network meta-analysis.
Topics: Anti-Allergic Agents; Azathioprine; Chronic Disease; Chronic Urticaria; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Glycosides; Histamine Antagonists; Histamine H1 Antagonists; Humans; Immunosuppressive Agents; Methotrexate; Network Meta-Analysis; Omalizumab; Randomized Controlled Trials as Topic; Treatment Outcome; Urticaria | 2023 |
Beyond the NFAT Horizon: From Cyclosporine A-Induced Adverse Skin Effects to Novel Therapeutics.
Topics: Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Ligands; NFATC Transcription Factors | 2021 |
Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis.
Topics: China; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Glomerulonephritis, Membranous; Glucocorticoids; Humans; Immunosuppressive Agents; Infections; Kidney Failure, Chronic; Randomized Controlled Trials as Topic; Risk; Tacrolimus | 2019 |
Review of Toxic Epidermal Necrolysis.
Topics: Antigens, Differentiation, T-Lymphocyte; Apoptosis; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Epidermis; Fas Ligand Protein; Granulocyte Colony-Stimulating Factor; Granzymes; Humans; Immunoglobulins, Intravenous; Infliximab; Keratinocytes; Mucous Membrane; Perforin; Stevens-Johnson Syndrome; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2016 |
Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.
Topics: Animals; Calcineurin; Calcineurin Inhibitors; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Humans; Kidney Diseases; Tacrolimus | 2010 |
Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Topics: Calcineurin Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Drug Evaluation; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sirolimus; Tacrolimus; Treatment Outcome | 2011 |
Cyclosporine nephrotoxicity.
Topics: Acute Disease; Chronic Disease; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Kidney Diseases | 2003 |
The use of extracellular matrix probes and extracellular matrix-related probes for assessing diagnosis and prognosis in renal diseases.
Topics: Biomarkers; Chronic Disease; Cyclosporine; Cytokines; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Extracellular Matrix; Gene Expression; Graft Rejection; Humans; Kidney Diseases; Metalloproteases; Predictive Value of Tests; Tissue Inhibitor of Metalloproteinases | 2004 |
Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection.
Topics: Autoimmune Diseases; Chronic Disease; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Hepatitis C; Humans; Rheumatic Diseases; Tumor Necrosis Factor-alpha | 2007 |
Adverse drug interactions clinically important for the dermatologist.
Topics: Anti-Bacterial Agents; Antifungal Agents; Cyclosporine; Dermatology; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Histamine Antagonists; Humans; Methotrexate; Retinoids; Risk Factors | 1995 |
Drugs and toxins: fact and fancy.
Topics: Anti-Infective Agents; Ciprofloxacin; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Silicones; Toxins, Biological | 1999 |
7 trial(s) available for cyclosporine and Adverse Drug Event
| Article | Year |
|---|---|
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Salvage Therapy; Treatment Outcome; Viral Load; Young Adult | 2015 |
Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Blood Urea Nitrogen; Brain Injuries; Creatinine; Cyclosporine; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Immunosuppressive Agents; Kidney; Leukocyte Count; Male; Middle Aged; Neuroprotective Agents; Placebos; Prospective Studies; Treatment Outcome; Young Adult | 2009 |
Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial.
Topics: Adult; Aged; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged | 2010 |
Safety and efficacy of a fixed-dose cyclosporin microemulsion (100 mg) for the treatment of psoriasis.
Topics: Adult; Cyclosporine; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Emulsions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Psoriasis; Quality of Life; Treatment Outcome | 2011 |
FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.
Topics: Adult; Biopsy; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney; Kidney Transplantation; Lung; Male; Middle Aged; Propylene Glycols; Sphingosine; Time Factors | 2006 |
[Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients].
Topics: Adolescent; Adult; Carrier State; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Kidney Transplantation; Liver; Male; Middle Aged; Tacrolimus; Young Adult | 2007 |
The search for effective and safe disease control in psoriasis.
Topics: Calcineurin Inhibitors; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Psoriasis; PUVA Therapy; Treatment Outcome | 2008 |
25 other study(ies) available for cyclosporine and Adverse Drug Event
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A Proposed Approach for the Determination of the Bioequivalence Acceptance Range for Narrow Therapeutic Index Drugs in the European Union.
Topics: Biological Variation, Individual; Colchicine; Computer Simulation; Cyclosporine; Dose-Response Relationship, Drug; Drug Approval; Drug Compounding; Drug-Related Side Effects and Adverse Reactions; Europe; European Union; Everolimus; Humans; Models, Biological; Research Design; Sample Size; Tacrolimus; Therapeutic Equivalency; Therapeutic Index, Drug; Thyroxine; Treatment Failure | 2022 |
Upadacitinib for moderate-to-severe atopic dermatitis, in adults and adolescents 12 years and older: review of international and Japanese populations.
Topics: Adolescent; Adult; Cyclosporine; Dermatitis, Atopic; Drug-Related Side Effects and Adverse Reactions; East Asian People; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Severity of Illness Index; Treatment Outcome | 2023 |
Cyclosporine-Induced Posterior Reversible Encephalopathy Syndrome: An Adverse Effect in a Patient With Atopic Dermatitis.
Topics: Cyclosporine; Dermatitis, Atopic; Drug-Related Side Effects and Adverse Reactions; Humans; Posterior Leukoencephalopathy Syndrome | 2023 |
COVID-19 vaccine-induced Stevens-Johnson syndrome.
Topics: Administration, Oral; COVID-19; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Male; Middle Aged; SARS-CoV-2; Skin; Stevens-Johnson Syndrome; Treatment Outcome | 2021 |
Unexpected overdose of oral cyclosporine in a kidney transplant patient: a case report.
Topics: Aged; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Male | 2023 |
Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3 in human renal tubule cells.
Topics: Aged; Aged, 80 and over; Apoptosis; Calcineurin Inhibitors; CD55 Antigens; Cell Line; Cell Survival; Complement Membrane Attack Complex; Complement System Proteins; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation; Graft Rejection; Humans; Kidney Diseases; Kidney Transplantation; Kidney Tubules; Male; MAP Kinase Signaling System; Membrane Cofactor Protein; Middle Aged; Phosphorylation; RNA, Small Interfering; Suppressor of Cytokine Signaling 3 Protein; Tacrolimus | 2018 |
Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Male; Prospective Studies; Tacrolimus; Treatment Outcome; Young Adult | 2019 |
Prediction of clinically relevant safety signals of nephrotoxicity through plasma metabolite profiling.
Topics: Animals; Captopril; Cyclosporine; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Diseases; Lisinopril; Male; Metabolome; Metabolomics; Phenytoin; Rats; Rats, Wistar | 2013 |
Classification of Cholestatic and Necrotic Hepatotoxicants Using Transcriptomics on Human Precision-Cut Liver Slices.
Topics: Acetaminophen; Aged; Benzofurans; Bile Acids and Salts; Chloramphenicol; Chlorpromazine; Cholestasis; Colchicine; Cyclosporine; Diethylnitrosamine; Drug-Related Side Effects and Adverse Reactions; Ethinyl Estradiol; Female; Gene Expression Profiling; Hepatocytes; Humans; Liver; Male; Methyltestosterone; Middle Aged; Necrosis; Phenotype; Toxicogenetics; Young Adult | 2016 |
Possible mechanism by which rapamycin increases cyclosporine nephrotoxicity.
Topics: Cell Cycle; Cell Division; Cell Survival; Cells, Cultured; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Kidney Tubules, Proximal; Sirolimus | 2008 |
The top 10 things nephrologists wish every primary care physician knew.
Topics: Aluminum; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antacids; Blood Pressure; Blood Urea Nitrogen; Cardiovascular Diseases; Cathartics; Chronic Disease; Contraindications; Creatinine; Cyclosporine; Disease Progression; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Evidence-Based Medicine; Glomerular Filtration Rate; Humans; Hypertension; Immunosuppressive Agents; Kidney Diseases; Magnesium; Nephrolithiasis; Nephrology; Phosphates; Primary Health Care; Proteinuria; Recombinant Proteins; Referral and Consultation; Tacrolimus; Urinalysis | 2009 |
Colchicine: serious interactions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Clofibric Acid; Colchicine; Cyclosporine; Drug Interactions; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Gout; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrolides; Muscular Diseases; Neurotoxicity Syndromes; Phenindione; Renal Insufficiency | 2008 |
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies.
Topics: Acetylglucosaminidase; Animals; Biomarkers, Pharmacological; Blood Urea Nitrogen; Cell Adhesion Molecules; Cisplatin; Creatinine; Cyclosporine; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Gentamicins; Histocytochemistry; Kidney; Kidney Function Tests; Male; Oligonucleotide Array Sequence Analysis; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reperfusion Injury; ROC Curve; Thioacetamide | 2010 |
Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells.
Topics: Acetaminophen; Amiodarone; Blotting, Western; Cell Survival; Chemical and Drug Induced Liver Injury; Cluster Analysis; Cyclosporine; Drug-Related Side Effects and Adverse Reactions; Electrophoresis, Gel, Two-Dimensional; Hep G2 Cells; Humans; Pharmaceutical Preparations; Protein Biosynthesis; Protein Processing, Post-Translational; Proteins; Proteomics; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Analysis of spontaneous adverse drug reaction (ADR) reports using supplementary information.
Topics: Adverse Drug Reaction Reporting Systems; Biostatistics; Creatinine; Cyclosporine; Databases, Factual; Diuretics; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Humans; Immunosuppressive Agents; Kidney Transplantation; Likelihood Functions; Models, Statistical; Netherlands; Odds Ratio; United States; United States Food and Drug Administration | 2011 |
Adequate immunotoxicity testing in drug development.
Topics: Animals; Antibody Formation; Azathioprine; Cyclosporine; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme-Linked Immunosorbent Assay; Female; Hemocyanins; Immunity; Immunoglobulin G; Immunoglobulin M; Immunosuppressive Agents; Indicators and Reagents; Male; Prednisolone; Rats; Toxicity Tests | 2004 |
[Visual cortes--is it a concern?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blindness, Cortical; Carmustine; Cathartics; Cholinergic Antagonists; Cisplatin; Cyclosporine; Dopamine Agents; Drug-Related Side Effects and Adverse Reactions; Hallucinations; Humans; Interferons; Serotonin Agents; Tacrolimus; Vidarabine; Vincristine; Visual Cortex | 2007 |
Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia.
Topics: Administration, Topical; Alopecia; Animals; Cyclophosphamide; Cyclosporine; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Hair Follicle; Ligands; Mice; Mice, Inbred C57BL; Tacrolimus | 1997 |
Pharmaceutical proteomics.
Topics: Animals; Cyclosporine; Drug Design; Drug-Related Side Effects and Adverse Reactions; Epoxy Compounds; Gene Expression; Gene Expression Profiling; Humans; Liver; Proteome | 2000 |